Table 2.

Optimal grouping according to ΔBMI computed through the recursive partitioning algorithm with respects to the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS)

	Pembrolizumab cohort			Chemotherapy cohort
	ORR	PFS	OS	ORR	PFS	OS
ΔBMI (%) computed cut-off	+1.4	+1.4	+1.4	+7.1	−6.8	−2.2
≥cut off	173 (24.0%)	183 (22.9%)	183 (22.9%)	36 (8.8%)	345 (83.3%)	266 (64.3%)
<cut-off	548 (76.0%)	616 (77.1%)	616 (77.1%)	375 (91.2%)	69 (16.7%)	148 (35.7%)

BMI, body mass index.